Zevra Therapeutics, Inc. delivered positive financial results in Q1 2026, underpinned by its lead orphan drug MIPLYFFA targeting Niemann-Pick Disease Type C. The company has streamlined its asset base through divestiture of the SDX portfolio to focus on core rare disease therapies, while appointing a new CFO to drive financial strategy. Operating within a challenging regulatory environment characterized by healthcare reforms in the U.S. and Europe, Zevra leverages orphan drug exclusivity to maintain pricing power and market niche leadership. Risks from evolving government reimbursement policies and cybersecurity remain key watchpoints as Zevra advances growth via commercialization expansion and regulatory compliance.